Baicalin is an inhibitor of subgroup J avian leukosis virus infection

•Baicalin possesses an antiviral effect on ALV-J by inhibiting viral mRNA and protein level in a dose- and time-dependent manner.•Baicalin specifically targets virus internalization and reduces the infectivity of ALV-J particles.•Baicalin effectively blocked ALV-J infection in DF-1 cells and might b...

Full description

Saved in:
Bibliographic Details
Published in:Virus research 2018-03, Vol.248, p.63-70
Main Authors: Qian, Kun, Kong, Zheng-Ru, Zhang, Jie, Cheng, Xiao-Wei, Wu, Zong-Yi, Gu, Cheng-Xi, Shao, Hong-Xia, Qin, Ai-Jian
Format: Article
Language:English
Subjects:
Avian leukosis virus subgroup J
Baicalin
Inhibition
Virus infection
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Baicalin possesses an antiviral effect on ALV-J by inhibiting viral mRNA and protein level in a dose- and time-dependent manner.•Baicalin specifically targets virus internalization and reduces the infectivity of ALV-J particles.•Baicalin effectively blocked ALV-J infection in DF-1 cells and might be considered as a prevention antiviral agents for ALV-J infection. Avian leukosis virus subgroup J (ALV-J) can cause great economic losses to the poultry industry worldwide. Baicalin, one of the flavonoids present in S.baicalensis Georgi, has been shown to have antiviral activities. To investigate whether baicalin has antiviral effects on the infection of ALV-J in DF-1 cells, the cells were treated with baicalin at different time points. We found that baicalin could inhibit viral mRNA, protein levels and overall virus infection in a dose- and time-dependent manner using a variety of assays. Baicalin specifically targeted virus internalization and reduced the infectivity of ALV-J particles, but had no effect on the levels of major ALV-J receptor and virus binding to DF-1 cells. Collectively, these results suggest that baicalin might have potential to be developed as a novel antiviral agent for ALV-J infection.
ISSN:0168-1702
1872-7492
DOI:10.1016/j.virusres.2018.02.017